INVESTORS
About
The company has a product for blood biomarker testing. The product is ready for the market in 2019. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark.
Investors
If you are interested in our ongoing IPO offer, you can subscribe - read more under IPO and listing. The subscription period runs from January 20, 2020 - February 7, 2020. Planned date for listing on Nasdaq, First North Growth Market, Stockholm is March 2, 2020.
Qlife Holding AB aims to ease the market's valuation of the company through clear information.
Egoo.health
The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.
Contact
If you have any questions about us or our ongoing IPO feel free to send us a message.
In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions.